Antibacterial Agents TRIZ Cases

A nitric oxide releasing macromolecule combined with hydrogel and anhydrous gel delivers controlled therapeutic gas.

A minocycline topical composition uses a monohydric aliphatic alcohol and polyol to enhance drug solubility and skin penetration.

Segmented Tp0751 fragments induce neutralizing antibodies to prevent bacterial dissemination and reduce chancre size in Treponema pallidum infections.

Continuous fatty acid feeding enables high Leptospira biomass production in protein-free media, eliminating adverse systemic reactions from animal serum.

Modifying amino acid positions 1 and 3 in cyclosporine analogues reduces immunosuppressive side effects while maintaining cyclophilin binding affinity.

Unstructured binding domains in trans-splicing RNA enhance on-target specificity and reduce off-target effects during therapeutic cell killing.

Compounds targeting intrinsically disordered proteins inhibit drug-resistant Mycobacterium tuberculosis growth, addressing rising MDR and XDR strain prevalence.

Formula IA, IB, or IC compounds modulate LXR activity to increase ApoE expression and reduce amyloid beta levels for treating melanoma and Alzheimer's disease.

Novel antimicrobial compounds inhibit bacterial cell division by targeting the FtsZ protein to eliminate pathogen viability.

Nucleic acids with defined sequences bind MCP-1 specifically, resolving the trade-off between interaction reliability and design complexity.

Segmented bedaquiline particles maintain therapeutic plasma levels to reduce pill burden and minimize bacterial resistance emergence.

Bile acids and salts block horizontal gene transfer to reduce antibiotic resistance spread without killing bacteria.

Tricyclic heterocycles resolve the specificity-reliability trade-off by targeting conserved acetylated lysine residues in BET proteins to treat cancer.

High-concentration bacteriophages induce lysis-from-without, bypassing antibiotic resistance and eliminating complex strain-matching requirements.

Replacing ototoxic aminoglycosides, this formulation uses Orbifloxacin, Mometasone Furoate, and Posaconazole to treat infections safely.

Crystallizing amorphous dicalcium hydrogen phosphate in organic solvents incorporates organic molecules into the lattice, preventing amorphous phase formation.

MVA prime adenovirus boost regimen overcomes pre-existing immunity to generate strong T cell and antibody responses.

Humanized monoclonal antibodies bind Clostridium difficile toxins with high affinity to neutralize infection-causing agents.

Dendrimeric segmentation of amino acid sequences creates protease-resistant structures that maintain broad-spectrum efficacy against Pseudomonas aeruginosa.

5-ALA derivatives form nanoparticles to overcome acute toxicity and short plasma half-life, enabling systemic treatment of inaccessible cancers.

Polypeptide covalently reactive analogs overcome noncovalent binding limits to enable stable Ab-antigen complexes and peptide bond hydrolysis.

N-aminated Gramicidin S analogues improve selectivity against bacteria while reducing hemolytic toxicity to mammalian cells via targeted chemical modifications.

Gold kiwifruit powder prebiotic supports Bacillus coagulans probiotic viability, resolving gastrointestinal side effects from traditional FODMAP ingredients.

Introducing a sulfur substituent into cyclopentanone derivatives reduces lipophilicity and improves water solubility, resolving poor oral bioavailability.

MHC multimers resolve weak monomer binding by increasing complex stability for reliable Borrelia diagnostics.

Crosslinked oligolactones and oligopeptides create durable tissue bonds that eliminate toxic risks from acrylate resorption.

A teat sealant formulation combines plant oil with bismuth subnitrate to create a stable physical barrier.

Seven-membered lactam ring structures resist metallo beta-lactamase hydrolysis to treat resistant infections.

Penicillium metabolites from fermented cheese lower cholesterol while inhibiting oxidative damage and inflammation.

A mutated Fc region polypeptide increases binding affinity to Fc receptors through specific amino acid substitutions.

Sulfonamide quinoline compounds transport zinc ions across bacterial membranes to disrupt cellular homeostasis and inhibit growth.

Acacia gum provides sustained adhesion while hydrophilic polymers slow xylitol dissolution for extended therapeutic release.

N-methyl Gly substitutions and PEG conjugation enhance in vivo retention of modified compstatin peptides.

Chimeric inhibitor proteins form covalent complexes with proteases, resolving reversible binding issues that restore enzyme activity.

Merging cannabidiol with brassinosteroids in topical formulations overcomes inadequate symptom reduction and slow action of single-agent treatments.

Antibodies targeting the LukGH heterodimer interface neutralize Staphylococcus aureus toxins across diverse strains.

Substituted isoquinoline compounds resolve the contradiction between inhibition effectiveness and targeting specificity to treat hypertension.

Ultrasonic irradiation accelerates synthesis of 2-amino-4-(4-bromophenyl)-6-ethoxypyridine-3,5-dicarbonitrile to overcome bacterial resistance.

Segmented bacterial populations and parasitic mediators resolve low throughput in antimicrobial peptide screening by enabling high-throughput detection.

Formula I pyrropyrimidine derivatives target specific kinase isoforms, balancing therapeutic effectiveness with reduced side effects.

An enzymatic composition generates biocides within the respiratory tract using peroxidase and oxidoreductase catalysts.

Pre-mixed paste components eliminate on-site mixing delays and complex vacuum equipment while maintaining reliable fixation.

Segmented plasmids expressing ESAT-6 family proteins overcome BCG limitations by delivering targeted immunity without adverse events.

Amorphous rifaximin polymorphs improve therapeutic consistency by reducing systemic absorption and minimizing bacterial resistance.

Removing transmembrane domains from Clostridium difficile toxins TcdA and TcdB creates safe immunogens that elicit neutralizing antibodies to prevent infection.

Intravenous oxazolidinone-quinolone hybrids bypass rapid gastrointestinal elimination to maintain therapeutic levels against Clostridium difficile.

Formula I compounds inhibit mutant IDH enzymes, blocking the conversion of alpha-ketoglutarate to 2-hydroxyglutarate.

Bi(III) compounds inhibit metallo-beta-lactamases via metal replacement, restoring beta-lactam antibiotic activity against resistant bacteria.